The goal of experimental clinical protocols using peptide antigen for active vaccination and
treatment of patients with metastatic cancer is to induce a vigorous cytotoxic T lymphocyte
(CTL) response against the immunizing antigen, and thereby against tumor cells expressing
the antigen. However, the magnitude and breadth of human CTL responses induced by
peptide immunization, and in particular against antigens expressed by normal tissues as
well as tumors, is not well characterized. This issue was examined by characterizing CTL …